98%
921
2 minutes
20
Synthetic immune-stimulatory drugs such as agonists of the Toll-like receptors (TLR) 7/8 are potent activators of antigen-presenting cells (APCs), however, they also induce severe side effects due to leakage from the site of injection into systemic circulation. Here, we report on the design and synthesis of an amphiphilic polymer-prodrug conjugate of an imidazoquinoline TLR7/8 agonist that in aqueous medium forms vesicular structures of 200 nm. The conjugate contains an endosomal enzyme-responsive linker enabling degradation of the vesicles and release of the TLR7/8 agonist in native form after endocytosis, which results in high TLR agonist activity. In a mouse model, locally administered vesicles provoke significantly more potent and long-lasting immune stimulation in terms of interferon expression at the injection site and in draining lymphoid tissue compared to a nonamphiphilic control and the native TLR agonist. Moreover, the vesicles induce robust activation of dendritic cells in the draining lymph node .
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7116109 | PMC |
http://dx.doi.org/10.1021/jacs.0c01928 | DOI Listing |
Carbohydr Polym
November 2025
State Key Laboratory of Radiation Medicine and Protection, School for Radiological and Interdisciplinary Sciences (RAD-X), Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou 215123, China. Electronic address:
Combining radiotherapy with immunotherapy holds promise for treating solid tumors and metastases, but challenges persist, including hypoxia-induced immunosuppression and immune-related adverse events from off-target toxicity. To address this, we engineered an in-situ formed hydrogel by crosslinking hyaluronic acid and polyvinyl alcohol with a reactive oxygen species (ROS)-responsive linker (3-aminophenylboronic acid). This hydrogel leverages radiotherapy-induced ROS within the tumor microenvironment to trigger localized release of nitric oxide (NO) and the toll-like receptor 7/8 (TLR7/8) agonist R848.
View Article and Find Full Text PDFAdv Healthc Mater
September 2025
Department of Chemistry, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon, Hong Kong, 999077, China.
Combination of chemotherapy and cancer immunotherapy has shown substantial clinical promise. However, the immunosuppressive tumor microenvironment (TME) poses a critical barrier to this combination therapy. Here, a tumor lysosome-targeted immunomodulatory strategy based on a biomimetic nanoadjuvant is presented, which effectively overcomes the immunosuppressive TME and demonstrates enhanced therapeutic efficacy when combined with chemotherapy.
View Article and Find Full Text PDFBiomater Sci
September 2025
State Key Laboratory of Polymer Science and Technology, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China.
Systemic immunotoxicity caused by off-target activation is still a critical obstacle to clinical translation of imidazoquinoline (IMDQ) drugs, a kind of TLR7/8 agonist. Here, we present an ultrasound-responsive, azide-modified IMDQ nano-prodrug (IMDQ-N NPs) that enables spatiotemporally controlled activation through ultrasound, improving the selectivity and safety. Concomitantly, riboflavin-based sonosensitizers were co-delivered to these nanoparticles, increasing their local concentration surrounding the prodrug, achieving a 12.
View Article and Find Full Text PDFChem Commun (Camb)
August 2025
Center for Drug Delivery System Research, School of Medicine, Shaoxing University, 900 Chengnan Avenue, Shaoxing, Zhejiang 312000, China.
The TLR7/8 agonist imidazoquinoline (IMDQ), 1-(4-(amino-methyl)benzyl)-2-(ethoxymethyl)-1-imidazo[4,5-]quinolin-4-amine, conjugated to chitosan was found to be a superior adjuvant to aluminum salts for vaccination against tumor-associated carbohydrate antigens.
View Article and Find Full Text PDFMacromol Biosci
August 2025
Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Triple-negative breast cancer (TNBC) remains a formidable clinical challenge due to its molecular heterogeneity and resistance to conventional therapies. This study presents a high-integrity nanoemulsion (NE) formulation designed to enhance the delivery and stability of the Toll-like receptor 7/8 (TLR7/8) agonist resiquimod (R848) for immunotherapy. Neutral and negatively charged NEs were developed with and without the reactive lipophilic compound ricinoleic acid.
View Article and Find Full Text PDF